Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · GLAND

GLAND

HealthcarePharmaceuticals & Biotechnology₹53281 cr market cap
₹3286.80 ▲ +1.74% today As of 19 Nov 2026
52-week low ₹1596.8052-week high ₹3385.90

-4.6% from the 52-week high · +102.3% above the low

Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-11-20. The firm specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmology segments. The firm provides contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a variety of delivery systems. Its products are available in liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns, Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients. Its products are sold across various countries, which include United States, Europe, Canada, and others.

The short version. GLAND reported revenue of ₹1,834 crore for Sep 2026, up 23.3% from a year earlier. Net profit was ₹291 crore (up 58.2% year on year). Return on equity was 9.9% in Mar 2026. Promoter holding was 45.75% in Sep 2026, down 6.08 points over 8 quarters.

1 · The price

How has the stock traded?

GLAND trades 4.6% below its 52-week high and 102.3% above its 52-week low.

Change over period: —

1M+7.0%
3M+13.7%
6M+45.4%
1Y+80.5%

2 · The business

Is it growing?

Sales, year on year+23.3%

Sep 2026 revenue of ₹1,834 cr.

Profit, year on year+58.2%

Sep 2026 net profit of ₹291 cr.

Net margin15.9%

3.5 pts higher than a year earlier.

3-year growth9.6% profit

Revenue compounded at 20.4% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue18341800174316951487150614251384
Net profit291317367261184215187205
Net margin %15.917.621.015.412.414.313.114.8
EPS (₹)17.6219.2122.2615.8711.1513.0811.3212.42

Annual

FY2026FY2025FY2024FY2023FY2022FY2021
Revenue643156175665362544013463
Net profit10276997727811212997
Net margin %16.012.413.621.527.528.8
EPS (₹)62.3542.446.947.4273.7560.94

3 · The quality

How well does it turn capital into profit?

Return on equity was 9.9% in Mar 2026; debt to equity is 0.02.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %9.97.68.89.8
Return on capital %13.711.412.513.2
EBITDA margin %28.525.425.831.3
Net margin %15.212.013.220.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR20.4%13.4%
Profit CAGR9.6%0.6%
Debt to equity0.02
Interest cover45.0x
Current ratio4.68
P/E ratio43.2

4 · The owners

Who holds it, and are they adding?

Promoter holding45.75%

Down 6.08 pts over 8 quarters.

Foreign institutions10.36%

Up 5.32 pts over 8 quarters.

Domestic institutions33.21%

Down 1.59 pts over 8 quarters.

Mutual fund schemes177

+42 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter51.8351.8351.8351.8351.8351.8351.7745.75-6.08
FII5.046.97.397.917.587.38.7410.36+5.32
DII34.833.2732.8532.6432.9833.3530.4433.21-1.59
Public8.337.997.937.637.617.529.0510.66+2.33

Mutual fund holdings · Oct 2026

177 schemes hold this stock

135 the month before.

  • DSP Healthcare Fund6.61% of NAV
  • UTI - MNC Fund4.52% of NAV
  • UTI - Healthcare Fund3.89% of NAV
  • ADITYA BIRLA SUN LIFE MNC FUND3.82% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND3.72% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund3.71% of NAV
  • SAMCO ELSS TAX SAVER FUND3.66% of NAV
  • SAMCO SMALL CAP FUND3.53% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for GLAND are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about GLAND

What is the GLAND share price?

GLAND (GLAND) last closed at ₹3,286.80, up 1.74% on the day. Its 52-week range is ₹1,596.80 to ₹3,385.90.

What is the market cap of GLAND?

GLAND has a market capitalisation of about ₹53,281 crore. Its price-to-earnings ratio is 43.2.

How are GLAND's latest results?

GLAND reported revenue of ₹1,834 crore for Sep 2026, up 23.3% from a year earlier. Net profit was ₹291 crore (up 58.2% year on year). Return on equity was 9.9% in Mar 2026. Promoter holding was 45.75% in Sep 2026, down 6.08 points over 8 quarters.

Who owns GLAND?

As of Sep 2026, shareholding was: Promoter 45.75%, FII 10.36%, DII 33.21%, Public 10.66%.

How many mutual funds hold GLAND?

177 mutual fund schemes held GLAND in October 2026. That compares with 135 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 14 Aug 2025 · Final Dividend - Rs. 18
  • 16 Aug 2024 · Final Dividend - Rs. 20

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.